

Ohio Board of Nursing www.nursing.ohio.gov

17 South High Street, Suite 400 • Columbus, Ohio 43215-7410 • (614) 466-3947

(Original New Drug Applications: FDA)				
Generic Name	Trade Name	Indication(s)	CPG Action/Date	
October 2012				
Bupivacaine Liposome Injection Formulary Pg. 19	Exparel	Central Nervous System Agents: Injectable Local Anesthetics. Indicated for administration into the surgical site to produce postsurgical analgesia.	1/14/13 CTP holder may prescribe.	
Articaine Hydrochloride/ Epinephrine Bitartrate Injection Formulary Pg. 19	Orabloc	Central Nervous System Agents: Injectable Local Anesthetics. Indicated for local, infiltrative, or conductive anesthesia in both simple and complex dental procedures.	1/14/13 CTP holder may prescribe.	
Sodium Picosulfate/ Magnesium Oxide/ Citric Acid	Prepopik	Gastrointestinal Agents: Laxatives: Bowel Evacuants. Indicated for cleansing the colon as a preparation for	1/14/13 CTP holder may prescribe.	
Formulary Pg. 21 Carfilzomib Formulary Pg. 29	Kyprolis	colonoscopy in adults. Antineoplastic Agents: Proteasome Inhibitors. Indicated for the treatment of patients with multiple myeloma who have received at least 2 prior therapies.	1/14/13 CTP holder May NOT prescribe.	
Florbetapir F 18 Injection	Amyvid	Diagnostic Aids: In Vivo Diagnostic Aids. Indicated for positron emission tomography imaging of the brain in adults patients with cognitive impairment who are being evaluated for Alzheimer disease and other causes of cognitive decline.	1/14/13 An APN with or without prescriptive authority may order a diagnostic test within their scope of practice.	
Formulary Pg. 29				

New Drugs January 2013

1

Novem	ber 2013	
Natazia	Endocrine & Metabolic Agents: Sex Hormones: Contraceptive Hormones. Indicated for	1/14/13 CTP holder may prescribe.
Korlym	Endocrine & Metabolic Agents: Uterine-Active Agents: Abortifacients. Indicated for controlling hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing syndrome who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for	1/14/13 CTP holder May NOT prescribe.
Tudorza Pressair	Respiratory Agents: Bronchodilators. Indicated for the long term maintenance treatment of bronchospasm with chronic obstructive	1/14/13 CTP holder may prescribe.
Omeclamox -Pak	pulmonary disease.Gastrointestinal Agents:Helicobacter pyloriAgents.Indicated for thetreatment of adults withH. pylori infection andduodenal ulcer disease(active or 1 year history)to eradicate H. pylori toreduce the risk ofduodenal ulcer	1/14/13 CTP holder may prescribe.
Zaltrap	recurrence. Antineoplastic Agents: Kinase Inhibitors. Indicated for the treatment of patients with metastatic colorectal cancer that is	1/14/13 CTP holder May NOT prescribe.
	Natazia Korlym Tudorza Pressair Omeclamox -Pak	Agents: Sex Hormones: Contraceptive Hormones. Indicated for contraception and heavy menstrual bleeding.KorlymEndocrine & Metabolic Agents: Uterine-Active Agents: Abortifacients. Indicated for controlling hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing syndrome who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery.Tudorza PressairRespiratory Agents: Bronchodilators. Indicated for the long term maintenance treatment of bronchospasm with chronic obstructive pulmonary disease.Omeclamox -PakGastrointestinal Agents: Helicobacter pylori Agents. Indicated for the treatment of adults with H. pylori infection and duodenal ulcer disease (active or 1 year history) to eradicate H. pylori to reduce the risk of duodenal ulcer recurrence.ZaltrapAntineoplastic Agents: Kinase Inhibitors. Indicated for the treatment of patients with metastatic

progressed following oxaliplatin-containing regimen, in combination with irinotecan, leucovorin, and 5-	
regimen, in combination with irinotecan, leucovorin, and 5-	
with irinotecan, leucovorin, and 5-	
leucovorin, and 5-	
fluorouracil.	
December 2012	
Mirabegron Myrbetriq Renal & Genitourinary 1/14/13	
Agents: Urinary CTP holder may	
Acidifiers. prescribe.	
Indicated for the	
treatment of overactive	
bladder with symptoms	
of urge urinary	
incontinence, urgency,	
Formulary Pg. 14 and urinary frequency.	
Azelastine Dymista Respiratory Agents: 1/14/13	
Hydrochloride/ Dynista Respiratory Agents. 1714/13 CTP holder may	
seasonal allergic rhinitis	
in patients 12 years and	
Formulary Pg. 14 older.	
Phentermine/QsymiaCentral Nervous System1/14/13	
TopiramateAgents: Anorexiants.CTP holder may	
Indicated as an adjunct NOT prescribe.	
to a reduce calorie diet	
and increased physical	
activity for chronic	
weight management in	
Formulary Pg. 16 adult patients.	
Glutamine NutreStore Gastrointestinal Agents: 1/14/13	
(L-Glutamine) Glutamine. CTP holder may	
Indicated for the prescribe.	
treatment of short bowel	
syndrome in patients	
receiving specialized	
nutritional support when	
used in conjunction with	
a recombinant human	
growth hormone that is	
approved for this	
Formulary Pg. 21 indication.	
Elvitegravir/ Stribild Anti-Infectives, 1/14/13	
Cobicistat/ Systemic: Antiretroviral Physician Initiate	
Emtricitabine/ Agents: Fusion Physician Consu	lt
Tenofovir Disoproxil Inhibitors.	
Fumarate Oral Indicated as a complete	
regimen for the	

		infection in adults who	
Formulan Dr. 04		are antiretroviral	
Formulary Pg. 24 Benzyl Alcohol	Ulesfia	treatment-naive Dermatological Agents:	1/14/13
Denzyi Alconol	Olesila	Scabicides/	CTP holder may
		Pediculicides.	prescribe.
		Indicated for the topical	
		treatment of head lice	
		infestation in patients 6	
Formulary Pg. 25		months and older.	
Mitomycin	Mitosol	Ophthalmic Agents:	1/14/13
Witterriyein	Milloool	Ophthalmic Surgical	CTP holder May
		Adjuncts.	NOT prescribe.
		Indicated for use as an	
		adjunct to ab externo	
Formulary Pg. 27 Enzalutamide	Xtandi	glaucoma surgery.	1/14/13
Enzalutamide	Xiandi	Antineoplastic Agents: Hormones:	Physician Initiated/
		Antiandrogens.	Physician Consult
		Indicated for the	for CTP holder with
		treatment of patients	SCA with physician
		with metastatic	specializing in
		castration-resistant	Hematology/
		prostate cancer who	Oncology
Formulary Pg. 27		have previously received docetaxel.	
Bosutinib	Bosulif	Antineoplastic Agents:	1/14/13
		Kinase Inhibitors.	CTP holder May
		Indicated for the	NOT prescribe.
		treatment of adult	
		patients with chronic,	
		accelerated, or blast phase Philadelphiw	
		chromosome-positive	
		chronic myelogenous	
		leukemia with resistance	
		or intolerance to prior	
Formulary Pg. 29		therapy.	

New Drugs Indications/ Warnings January 2013
(Nave Drawn Indiantiana/ Diani, Dav. Manainana, EDA

(New Drug Indications/ Black Box Warnings: FDA			
Generic Name	Trade Name	Indication(s)	CPG Action/Date
	Octob	per 2013	
None			
	Novem	ber 2013	
None			
	Decem	ber 2013	
Rivaroxaban Formulary Pg. 7	Xarelto	Hematological Agents: Anticoagulants: Selective Factor Xa Inhibitor. New indication for reducing the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation.	Current: Physician Initiated/ Physician Consult 1/14/13 No Change
Difluprednate Ophthalmic	Durezol	Ophthalmic Agents: Corticosteroids. New indications for the treatments of endogenous anterior uveitis.	Current: Physician Initiated/ Physician Consult 1/14/13 No Change
Formulary Pg. 26			

Formulary Revision Requests January 2013 (Original New Drug Applications: FDA)

Generic Name	Trade Name	Indication(s)	CPG Action/Date			
	Melissa A. Telenko, MSN, FNP-BC					
Bexarotene Oral	Targretin	Dermatological Agents: Rexinoids. Indicated for the topical treatment of cutaneous lesions in patients with cutaneous T-cell lymphoma who have refractory of persistent disease after other therapies or who have not tolerated other therapies.	Current: Not currently listed in Formulary. 1/14/13 Physician Initiated/ Physician consult for CTP holder with SCA w/ physician specializing in Dermatology or Hematology/ Oncology			
Bexarotene Topical		Indicated for the topical treatment of cutaneous lesions in patients with cutaneous T-cell				

		1	1
Not Currently on Formulary Methoxsalen Oral	Oxsoralen Ultra	lymphoma (CTCL) (Stage IA and IB) who have refractory or persistent disease after other therapies or who have not tolerated other therapies. Requesting: Physician Initiated/ Physician Consult with a dermatologist. Dermatologist. Photochemotherapy	Current: CTP holder may
		Agents. Indicated for the symptomatic control of severe, recalcitrant, disabling psoriasis not adequately responsive to other forms of therapy and when the diagnosis has been supported by biopsy.	NOT prescribe. 1/14/13 No change, discussion tabled until 5/20/13 CPG meeting.
Methoxsalen Topical	Oxsoralen	Indicated as a topical repigmenting agent in vitiligo, used in conjunction with controlled doses of ultraviolet A or sunlight. Requesting: Physician Initiated/ Physician Consult with a	
Formulary Pg. 25		dermatologist.	
	Michelle B	olles, ACNP	
Vancomycin	Vancomycin	Anti-Infective, Systemic: Vancomycin. Indicated for the treatment of antibiotic- associated pseudomembranous colitis caused by <i>Clostridium difficile</i> and enterocolitis caused by <i>Staphylococcus aureus</i> . Requesting: CTP holder may prescribe.	Current: CTP holder may prescribe in institutional setting ONLY for preop prophylaxis according to institutional protocol based on current national guidelines or Physician Initiated/ Physician Consult.

Formulary Pg. 22			1/14/13 CTP holder may prescribe in institutional setting according to institutional protocol or Physician Initiated/ Physician Consult.
Enoxaparin	Lovenox	Hematological Agents: Anticoagulants: Low Molecular Weight Heparins. Indicated for the treatment of acute ST- segment elevation myocardial infarction, for the prophylaxis of deep vein thrombosis, for the prophylaxis of ischemic complications of unstable angina, for the inpatient treatment of acute DVT with or without pulmonary embolism, and the outpatient treatment of acute DVT without pulmonary embolism. Requesting: CTP holder	Current: Physician Initiated/ Physician Consult 1/14/13 CTP holder may prescribe.
Formulary Pg. 7 Midazolam Injectable	Versed	may prescribe. Central Nervous System Agents: General Anesthetics: Benzodiazepines. Indicated for sedation, anxiolysis and amnesia prior to or during sort diagnostic therapeutic or endoscopic procedures, for induction of general anesthesia, to supplement nitrous oxide and oxygen, infusion for sedation of intubated and mechanically intubated patients as a component	Current: CTP holder may prescribe only for sedation levels up to moderate, and only in institutional settings per institutional standards.

			11
		or anesthesia or during	
		treatment in a critical	
		care setting.	
		Requesting: CTP holder	
		may prescribe for	
		sedation levels up to	
		moderate, and only in	
		institutional settings per	
Formulary Pg. 19		institutional standards.	
¥		·	
	Jill M. Wa	arner, CNP	
Aminolevulinic Acid	Levulan Kerastick	Dermatological Agents:	Current:
HCL		Photochemotherapy.	CTP holder may
		Indicated for the	NOT prescribe.
		treatment of non-	
		hyperkeratotic keratosis	1/14/13
		of the face or scalp.	Physician Initiated/
			Physician consult
			for CTP holder with
			SCA w/ physician
			specializing in
		Requesting: Physician	Dermatology
		Initiated/ Physician	Definitionegy
		Consult or CTP holder	
		may prescribe with SCA	
		with physician	
		specializing in	
Formulary Pg. 25		dermatology.	
· • • • • • • • • • • • • • • • • • • •			

Review of Prescribing Designations PI/PC and CTP Holder May <u>NOT</u> Prescribe

Hematological Agents (January 2013)				
Drug Category/ Drug Name	Indication(s): If reviewing a specific drug in a drug category	Current Prescribing Designation	CPG Action/Date	
	Hematopoie	etic Agents		
Thrombopoietin Mimetic Agents: Romiplostim Injection (Nplate)	Hematopoietic Agents: Thrombopoietin Mimetic Agents. Indicated for the treatment of thrombocytopenia in patients with chronic ITP who have had an insufficient response to corticosteroids,	CTP holder May NOT prescribe.	Physician Initiated/ Physician Consult for CTP holder with SCA with physician specializing in Hematology/ Oncology	

	immunoglobulins, or		
Formulary Pg. 6	splenectomy.		
Colony-Stimulating Factors	Hemotopoietic Agents: Colony Stimulating Factors.	Physician Initiated/ Physician Consult for CTP holder with SCA with physician specializing in	1/14/13 No Change
Formulary Pg. 6 Filgrastim Injection (Neupogen)	Hematopoietic Agents: Colony Stimulating Factors. Indicated for reducing the incidence of febrile neutropenia in patients receiving chemotherapy, reducing duration of neutropenia in patients with non myeloid malignancies undergoing bone marrow transplantation, for mobilization of hematopoietic progenitor cells into the peripheral blood for collection, and for chronic administration to	 Specializing In Hematology/ Oncology. CTP holder May NOT prescribe. Physician Initiated/ Physician Consult for CTP holder with SCA with a physician specializing in Hematology/Oncology. 	1/14/13 Physician Initiated/ Physician Consult for CTP holder with SCA with a physician specializing in Hematology/Oncolo gy
Formulary Pg. 6	reduce the incidence and duration of sequelae of neutropenia in patients with neutropenia.		
Pegfilgrastim Injection (Neulasta)	Hematopoietic Agents: Colony Stimulating Factors. Indicated to reduce the incidence of infection in patients receiving myelosupporessive anticancer drugs.	CTP Holder May NOT prescribe. Physician Initiated/ Physician Consult for CTP holder with SCA with a physician specializing in	1/14/13 Physician Initiated/ Physician Consult for CTP holder with SCA with a physician specializing in Hematology/
Formulary Pg. 6	-	Hematology/Oncology.	Oncology
Sargramostim (Leukine)	Hematopoietic Agents: Colony Stimulating Factors. Indicated for patients with non-Hodgkins lymphoma, acute lymphoblastic leukemia, and Hodgkin's disease undergoing autologous		1/14/13 Physician Initiated/ Physician Consult for CTP holder with SCA with a physician specializing in Hematology/ Oncology

		ſ	r
	BMT, and for patients who have undergone		
	allogeneic or autologous		
	BMT in whom		
Not Currently on	engraftment is delayed		
Formulary	or has failed.		
Stem Cell Mobilizers	Hematopoietic Agents:	Physician Initiated/	1/14/13
Plerixafor Injection	Stem Cell Mobilizers.	Physician Consult.	No Change
(Mozobil)	Indicated for use in		-
	combination to mobilize		
	hematopoietic stem		
	cells to the peripheral		
	blood for collection and		
	transplantation in		
	patients with non-		
Formulary Da 6	Hodgkin lymphoma and		
Formulary Pg. 6 Interleukins	multiple myeloma.	Dhysisian Initiated/	1/14/13
Oprelvekin	Hematopoietic Agents: Interleukins.	Physician Initiated/ Physician Consult for	No Change
(Neumega)	Indicated for the	CTP holder with SCA	No Change
(Neumegu)	prevention of severe	with a physician	
	thrombocytopenia and	specializing in	
	reduction of the need for	Hematology/Oncology.	
	platelet transfusion		
	following		
	myelosuppressive		
Formulary Pg. 6	chemotherapy.	075	
Thrombopoietin	Hematopoietic Agents:	CTP holder May NOT	1/14/13
Receptor Agonist	Thrombopoietin Receptor Agonist.	prescribe.	Physician Initiated/ Physician Consult
Eltrombopag (Promacta)	Indicated for the		for CTP holder with
(FIOMACIA)	treatment of		SCA with a
	thrombocytopenia in		physician
	patients with chronic		specializing in
	ITP who have an		Hematology/
	insufficient response to		Oncology
	corticosteroids,		
	immunoglobulins, or		
	splenectomy.		
Formulary Pg. 6 Antiplatelet Agents			
Glycoprotein	Antiplatelet Agents.	Physician Initiated/	1/14/13
Inhibitors	Glycoprotein Inhibitors.	Physician Consult	No Change
	Indicated for the	,	
	treatment of acute		
	coronary syndrome.		
Formulary Pg. 6			
T Officially F.Y. O			

	Anticoagulants				
Low Molecular Weight Heparins	Anticoagulants: Low Molecular Weight Heparins. Indicated for DVT prophylaxis in patients undergoing surgery at risk for thromboembolic complications or severely limited mobility, treatment of DVT,	gulants Physician Initiated/ Physician Consult	1/14/13 CTP holder may prescribe.		
Formulary Pg. 7 Antithrombin	prophylaxis of ischemic complications in unstable angina and non-Q wave MI, prevention of exercise- induced broncho- constriction, and acute STEMI.	Dhysisian Initiated/	1/1/1/12		
Antithrombin Agents Formulary Pg. 7	Anticoagulants: Antithrombin Agents. Indicated for the treatment of patients with hereditary AT-III deficiency in connection with surgical or obstetrical procedures of when they suffer from thromboembolism.	Physician Initiated/ Physician Consult	1/14/13 No Change		
Thrombin Inhibitors	Anticoagulants: Thrombin Inhibitors.	Physician Initiated/ Physician Consult	1/14/13 No Change		
Dabigatran Etexilate (Pradaxa) Formulary Pg. 7	Indicated to reduce the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation.				
Selective Factor Xa Inhibitor	Anticoagulants: Selective Factor Xa Inhibitor. Indicated for the prophylaxis of deep vein thrombosis (DVT), which may lead to pulmonary embolism (PE) and for the treatment of acute DVT and acute PE when	Physician Initiated/ Physician Consult	1/14/13 No Change		

			r
	administered in conjunction with		
	warfarin.		
Formulary Pg. 7			
Coumarin Anticoagulants	Anticoagulants: Coumarin Anticoagulants.	Physician Initiated/ Physician Consult	1/14/13 Physician Initiated/ Physician Consult
Warfarin Sodium (Coumadin)	Indicated to reduce the risk of death, recurrent MI, and thromboembolic events. For prophylaxis and/or treatment of thromboembolic complications associated with atrial fibrillation and/or cardiac valve replacement. For the prophylaxis and/or treatment of venous thrombosis and pulmonary embolism.		CTP holder may prescribe per institutional protocol.
Formulary Pg. 7			
	Coagı	ilants	
Heparin Antagonist	Coagulants: Heparin Antagonist.	CTP holder May NOT prescribe.	1/14/13 Physician Initiated/ Physician Consult
Protamine Sulfate Formulary Pg. 7	Indicated for the treatment of heparin overdosage.		CTP holder may prescribe per institutional protocol.
	Thromboly	tic Agents	
Thrombolytic	Thrombolytic Agents.	CTP holder May NOT	1/14/13
Agents		prescribe except for catheter occlusions.	No Change
Formulary Pg. 7	Thrombolytic Aconto:	Dhysisian Initiated/	This medication has
Recombinant Human Activated Protein (Xigris)	Thrombolytic Agents: Tissue Plasminogen Activators: Human Protein C. Indicated to reduce mortality in adult patients with severe sepsis who have a high risk of death.	Physician Initiated/ Physician Consult	This medication has been discontinued.
Formulary Pg. 7			

	Antisicklir	ng Agents	
Hydroxyurea (Droxia) Formulary Pg. 7 C1 Injector, Human	Antisickling Agents. Indicated to reduce the frequency of painful crises and to reduce the need for blood transfusions in adult patients with sickle cell anemia. Protein C1 Protein C1	CTP holder May NOT prescribe. Physician Initiated/ Physician Consult for CTP holder within sickle cell clinic only. Inhibitor CTP holder May NOT	1/14/13 Physician Initiated/ Physician Consult for CTP holder within sickle cell clinic only.
(Cinryze)	Indicated for routine prophylaxis against angioedema attacks in adolescent and adult patients with hereditary angioedema.	prescribe.	Physician Consult
Formulary Pg. 7 Kallikrein Inhibitor			
Ecallantide (Kalbitor)	Kallikrein Inhibitor. Indicated for treatment of acute attacks of hereditary angioedema in patients 16 years of age and older.	Physician Initiated/ Physician Consult	1/14/13 No Change
Formulary Pg. 7			
	Bradykinin	Inhibitors	
Icatibant (Firazyr) Formulary Pg. 7	Bradykinin Inhibitors. Indicated for treatment of acute attacks of hereditary angioedema in adults 18 years and older.	Physician Initiated/ Physician Consult	1/14/13 No Change
	Antihemoph	nilic Agents	
Antihemophilic Agents	Antihemophilic Agents.	Physician Initiated/ Physician Consult	1/14/13 No Change
Formulary Pg. 7	Antihemophilic Fac	tor Combinations	
Antihemophilic Factor/ von Willebrand Factor Complex (Factor VIII/VWF: AHF/VWF) (Humate, Wilate)	Antihemophilic Factor Combination. Indicated for the treatment and prevention of bleeding in adult patients with hemophilia A and in adults and children with	Physician Initiated/ Physician Consult	1/14/13 No Change

	von Willebrand disease.		
Formulary Pg. 7			
	Hemos	statics	
Hemostatics	Hemostatics: Systemic.	CTP holder May NOT	1/14/13
(systemic)	· · · · · · · · · · · · · · · · · · ·	prescribe.	No Change
Formulary Pg. 7			
Tranexamic Acid	Hemostatics: Systemic.	Physician Initiated/	1/14/13
	Indicated for the	Physician Consult	No Change
	treatment of cyclic		
	heavy menstrual		
Formulary Pg. 7	bleeding. Plasma Ex	knandors	
Dia a man Francisco da ma			4/4 4/4 0
Plasma Expanders	Plasma Expanders.	Physician Initiated/	1/14/13
		Physician Consult –	No Change
Formulary Da 7		except Albumin, CTP	
Formulary Pg. 7	Hen	holder may prescribe.	
Hemin	Hemin.	CTP holder May NOT	1/14/13
пенни	Indicated for the	prescribe.	No Change
	amelioration of recurrent	prescribe.	No Change
	attacks of acute		
	intermittent porphyria		
	temporally related to the		
	menstrual cycle in		
	susceptible women.		
Formulary Pg. 7			